EPIGRAL Epigral Q1 FY26 results (Apr–Jun 2025) and concall
Epigral reported a challenging Q1 FY26 with a 6% revenue degrowth to INR 615 crores, primarily due to plant maintenance and lower volumes. Despite this, the company maintained a strong EBITDA margin of 27% and significantly reduced its net debt to EBITDA to 0.60x. Strategic projects like the Chlorotoluene value chain were commissioned, and new chemistry for future growth is under evaluation, signaling a focus on long-term diversification and efficiency.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 |
|---|---|---|---|---|
| Revenue | 626 | 645 | 628 | 607 |
| EBITDA | 178 | 183 | 173 | 163 |
| Net profit | 81 | 104 | 87 | 161 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
